United States: Biobetters: The Advantages And Challenges Of Being Better

Last Updated: July 1 2015
Article by Irena Royzman and Andrew D. Cohen

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was passed as part of health reform signed into law by President Barack Obama in March 2010. The BPCIA created an abbreviated pathway for Food and Drug Administration approval of biologic medicinal products that are ''biosimilar'' to an already FDA-approved product. Because biologic drugs, also referred to as biologics, are complex molecules made in living organisms rather than chemically synthesized, biosimilars are not copies of an approved biologic product. Instead, the BPCIA requires a biosimilar to be ''highly similar'' to the approved product without any clinically meaningful differences in terms of safety, purity and potency.

The FDA recently approved the first U.S. biosimilar: Sandoz's biosimilar of Amgen's Neupogen, a blockbuster drug used to prevent infections in cancer patients. While the FDA currently is reviewing four other proposed biosimilars and additional applications for approval of biosimilar versions of some of the most successful biologic medicines are expected shortly, many innovators and biosimilar manufacturers are responding to the changing landscape for biologics by developing ''biobetters'': new and improved versions of biologic medicinal products.

While biobetters require discovery and an original Biologics License Application (BLA) with a full complement of pre-clinical and clinical data for marketing approval, they also offer many advantages. By offering a superior or longer-acting medicine, biobetters provide a competitive advantage over biosimilar products. In addition, unlike biosimilars, they generally would be entitled to patent protection and 12 years of non-patent exclusivity under the BPCIA.


Biobetters can provide a substantial difference in clinical efficacy, safety or convenience and they may have fewer side effects or less frequent dosing. Amgen's Neulasta, an improved long-acting version of Amgen's Neupogen that was approved by the FDA in 2002, is one of the early examples of biobetters. Neulasta consists of Neupogen with a covalently bound polyethylene glycol (PEG) molecule that allows Neulasta to be administered less frequently. While Neupogen is administered once daily during a chemotherapy cycle, Neulasta is administered only once per chemotherapy cycle. U.S. sales in fiscal year 2014 for Neulasta were approximately $3.8 billion as opposed to only $880 million for Neupogen, reflecting the commercial value of a biobetter.

Biobetter Strategies

Manufacturers are employing a number of strategies to create biosimilars and many more biobetters are being developed in the face of impending biosimilar competition.

Pegylation (i.e., the addition of PEG) is being used to create long-acting versions of successful biologics. In addition to Amgen's Neulasta, a number of companies have used pegylation to make biobetters of their own drugs or those of other innovators. For example, Roche created a pegylated biobetter of Amgen's Epogen that is sold as Mircera. In 2007, the FDA approved Mircera for once-monthly dosing to anemic patients as opposed to weekly dosing for Epogen. Last year, Biogen Idec obtained approval for Plegridy, a pegylated long-acting version of its own Avonex, a treatment for multiple sclerosis.

Innovators also are actively pursuing a number of strategies to create biobetters of some of the most successful antibody products. One such strategy is to prepare a fragment of the originator antibody that retains the efficacy of the antibody, but confers benefits in terms of delivery or safety. For example, Roche's Lucentis, approved to treat age-related macular degeneration and edema, is a fragment of Roche's Avastin antibody, a treatment for colon and other cancers. The antibody fragment may penetrate the eye's retina better than the full antibody and only Lucentis is approved for ophthalmic use.

Antibody-drug conjugates represent another approach to developing biobetters. Roche's Kadcyla, approved in 2013, is a recent example of that strategy. Kadcyla is a conjugate of a cancer-killing agent with Roche's Herceptin antibody, a blockbuster breast cancer treatment. The antibody inhibits a protein that is over-expressed in certain breast cancers. Kadcyla also delivers the cancer-killing agent site-selectively, a one-two punch.

Attempts to reduce a patient's unwanted immune reaction to chimeric antibodies, antibodies with mouse and human protein sequences, have led to the development of humanized biobetters, i.e., antibodies where many of the mouse sequences are replaced with human ones. Roche, as an example, is developing ocrelizumab, a humanized analog of the chimeric Rituxan antibody for treatment of multiple sclerosis. This humanized version of Rituxan is now in phase III clinical trials.

In 2013, Roche obtained approval of another humanized antibody, Gazyva, a Rituxan biobetter that is also known as ''Son of Rituxan.'' Gazyva, a therapy for chronic lymphocytic leukemia, is also engineered to more efficiently trigger an immune response and clear cancer cells. The FDA gave Gazyva a breakthrough therapy designation based on clinical evidence indicating that it offers a ''substantial improvement'' over available therapies, such as Rituxan. If approved for other Rituxan indications, Gazyva is poised to take over the Rituxan market, potentially before biosimilar competition.

Advantages of Biobetters

Biobetters have the potential to offer tremendous commercial advantages over originator or biosimilar drugs as well as to receive patent protection and market exclusivity.

Commercial Value

By providing a more effective or longer-acting medicine, biobetters create the potential to take over and control the market prior to entry of biosimilars of the originator drug. For example, in Europe, where biosimilars of Neupogen are marketed at a 20 percent to 30 percent discount over Neupogen, Amgen has retained significant market share by having Neulasta to offer patients.1 Neulasta, as a long-acting biobetter of Neupogen, provides advantages to patients that Neupogen or its biosimilars do not have. Similarly, although Granix, Teva's version of Amgen's Neupogen, has been on the U.S. market since 2013, Neulasta continues to be a blockbuster product in the U.S. due to the benefits it provides to patients.

Biobetters also have the potential to reduce healthcare costs due to greater therapeutic efficacy or by having to be administered less frequently, as in the case of Neulasta. Also, unlike biosimilars, biobetters are not faced with the burden of having to be similar to the originator biologic. This frees companies to use more modern and potentially less costly manufacturing methods. In addition, as a better or more convenient medicine, biobetters offer a marketing advantage over the originator biologic or its biosimilars.


Biobetters also are likely eligible for patent protection. Patents can potentially be obtained for the biobetter itself, a pharmaceutical composition of the biobetter, a method of treatment or manufacture. Biobetters may be eligible for all of the same types of patent protection available for originator biologics. Amgen, for example, obtained patent protection for its Neulasta biobetter. Similarly, Roche obtained patent protection for Mircera (a biobetter of Amgen's Epogen), Gazyva (a biobetter of Roche and Biogen's Rituxan antibody) and Kadcyla (a biobetter of Roche's Herceptin antibody).

Regulatory Advantages and Non-Patent Exclusivity

Biobetters, just as any new biologics, allow manufacturers to avoid the complex litigation provisions, a 12- year bar to final FDA approval and regulatory uncertainty associated with the BPCIA. Because biobetters are approved through submission of a full BLA rather than an abbreviated BLA (aBLA), they are not subject to the litigation provisions of the BPCIA and are not blocked by the originator biologic's 12 years of non-patent exclusivity provided in the BPCIA. Under the BPCIA, a biosimilar cannot receive final regulatory approval from the FDA and cannot be marketed until the reference biologic has enjoyed 12 years of marketing exclusivity from the time it was first licensed. By contrast, the FDA can approve biobetters at any point in time, and therefore biobetters can enter the market prior to the marketing of any biosimilars.

Further, while approval of a biologic through a traditional BLA with a full complement of pre-clinical and clinical data is much more costly than approval through submission of an aBLA, the BPCIA is still a largely untested regulatory pathway. To date, only Sandoz's biosimilar of Neupogen, known as Zarxio, has been approved through the BPCIA regulatory pathway. While Zarxio's approval earlier this year was a milestone event, it is unlikely to offer significant insight into the regulatory requirements for obtaining approval of complex biologics due to its simplicity. Zarxio is a small protein made in bacteria with no glycosylation (attached sugars). Biobetters, by being approved through submission of a traditional BLA, benefit from a more certain and established regulatory approval pathway.

As with other new biologics, the BPCIA provides a significant advantage to biobetters. Biobetters have the potential to receive their own 12 years of market exclusivity from biosimilar competition. The BPCIA automatically provides biobetters with that advantage if the regulatory application is filed by a company that is not related to or a licensee of the company that applied for or manufactured the originator biologic. When the company that applied for approval of the originator biologic seeks FDA approval of a biobetter of its own product, the biobetter will likely receive 12 years of market exclusivity as long as it is a true biobetter, i.e., it is (1) structurally different from the originator biologic and (2) provides a change in safety, purity or potency as compared to the originator product.2

Guidance from the FDA confirms that biobetters likely will be entitled to their own 12-year exclusivity.3 The FDA considers any of the following differences to be a structural modification of the originator biologic for purposes of the 12-year exclusivity provision of the BPCIA: ''any differences in amino acid sequence, glycosylation patterns, tertiary structures, post-translational events (including any chemical modifications of the molecular structure such as pegylation), and infidelity of translation or transcription, among others.'' The typical biobetters strategies, discussed above, all meet this requirement.

In assessing whether such structural differences result in a change in safety, purity or potency as compared to the originator product, the FDA intends to make a case-by-case determination based on information provided by the biobetter applicant about a ''measurable effect (typically demonstrated in preclinical or clinical studies and shown by relevant methods such as bioassays).'' The FDA recommends that the biobetter applicant present ''evidence that the change will result in a meaningful benefit to public health, such as a therapeutic advantage or other substantial benefit when compared to the previously licensed biological product.'' Since the goal of biobetter development is to provide a superior medicine that is meaningfully different in terms of safety, purity or potency, this further requirement should be readily met, providing the biobetter with 12 years of non-patent exclusivity against biosimilar entrants.

Challenges of Biobetters

Biobetters also pose formidable challenges. As with originator biologics, biobetter development is fraught with risk and requires significant research and development. Biobetters are bound to have a higher success rate than originator biologics due to a validated target for the biologic, but an improved biologic is far from certain and may require significant experimentation. In addition, biobetters may have new and unexpected side effects that are different from that of the originator biologic. Approval of a biobetter also requires a traditional BLA with a full complement of pre-clinical and clinical data. As a result, research and development costs for biobetters will be significantly greater than that for a biosimilar of an originator biologic and approach that of an originator biologic. But the development of the biobetter benefits from the established efficacy of the originator biologic and validated target.


Biobetters are here now, but, as biosimilar competition looms, biobetters may become the better approach for all biologics manufacturers. With the promise of 12 years of market exclusivity, the possibility of patent protection and the hope of capturing a market before competition arrives, the most important consequence of the BPCIA may not be the introduction of biosimilars, but the incentive for biobetters.

Originally published by Bloomberg BNA's Life Sciences Law & Industry Report.


1. Henry Grabowski et al., Biosimilar competition: lessons from Europe, Nature Reviews: Drug Discovery, 13, 99-100 (Feb. 2014).

2. 42 U.S.C. §§ 262(k)(7)(A) & (C).

3. FDA, Draft Guidance for Industry: Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act (Aug. 2014), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM407844.pdf.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Patterson Belknap Webb & Tyler LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Patterson Belknap Webb & Tyler LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions